GNbAc1
|
Monoclonal antibody
|
Assess the efficacy of HERV-W Env antagonist in MS
|
RRMS
|
NCT02782858
|
GSK239512
|
Histamine H, receptor antagonist
|
Evaluate whether it can remyelinate lesions in patients
|
RRMS
|
NCT01772199
|
Opicinumab (BIIB033)
|
Anti-lingo-1 monoclonal antibody
|
Efficacy, safety and dose tolerability for CNS remyelination
|
RRMS
|
NCT01864148
|
Domperidone
|
Dopamine D2 antagonist
|
Study myelin repair in patients with enhancing lesion by MRI
|
RRMS
|
NCT02493049
|
Clemastine Fumarate
|
Antihistaminic
|
Assessment of its tolerability as a remyelinating agent
|
RRMS
|
NCT02040298
|
Vaginal estriol
|
Estrogen
|
Evaluate the efficiency and remyelination role in female patients with urogenital symptoms
|
RRMS
|
NCT03774407
|
Liothyronine
|
Thyroid hormone
|
Safety and dose finding study of remyelination
|
RRMS, SPMS, PPMS
|
NCT02760056
|
Olesoxime
|
Cholesterol-like neuroprotectant
|
Measurement of remyelination by MRI
|
RRMS
|
NCT01808885
|
Natalizumab
|
Anti-integrin monoclonal antibody
|
Evaluate the remyelination capacity
|
RRMS
|
NCT00937677
|
Quetiapine fumarate
|
Atypical Antipsychotic
|
Safety and tolerability of this remyelinating agent in patients
|
RRMS, RPMS
|
NCT02087631
|
Alemtuzumab
|
Anti-CD52 monoclonal antibody
|
MRI measurement of remyelination
|
RRMS
|
NCT01395316
|
Adrenocorticotropic hormone (ACTH)
|
Hormone
|
Evaluate the effect of ACTH for treating demyelination in patients
|
RRMS, SPMS
|
NCT00854750
|
Bazedoxifene acetate
|
Selective estrogen receptor modulator
|
Test the efficacy of the drug as a remyelinating agent
|
RRMS
|
NCT04002934
|